Source comparison
MOTS-c Research: Comparison with Other Metabolic Peptides
MOTS-c AMPK activation → enhanced fat oxidation in muscle Preclinical strong; human clinical limited 2–3× weekly (research protocols) Short half-life (~4.5 hours); no Phase 3 human fat loss trials Promising metabolic modulator with strong mechanistic rationale
This comparison does not assign a generated winner or score.
- MOTS-c
- AMPK activation → enhanced fat oxidation in muscle
- Preclinical strong; human clinical limited
- 2–3× weekly (research protocols)
- Short half-life (~4.5 hours); no Phase 3 human fat loss trials
- Promising metabolic modulator with strong mechanistic rationale but insufficient human efficacy data for fat loss claims
- Tesofensine
- Dopamine/norepinephrine/serotonin reuptake inhibition → appetite suppression + thermogenesis
- Phase 2 human trials show 9.2% weight loss at 24 weeks
- Daily oral
- CNS side effects (insomnia, dry mouth); not FDA-approved
- Proven weight loss efficacy in humans but regulatory hurdles remain
- AOD-9604
- Fragment of hGH (C-terminal); claimed lipolytic effect
- Preclinical only; human trials failed primary endpoints
- Daily subcutaneous
- No credible human evidence for fat loss
- Marketing exceeds evidence. Avoid
- CJC-1295/Ipamorelin
- Growth hormone secretagogue stack
- Indirect (via GH/IGF-1 elevation); body recomp effects modest
- 3–5× weekly
- Fat loss secondary to lean mass gain; rebound possible
- Useful for body recomposition in conjunction with training. Not standalone fat loss
- Semaglutide (GLP-1)
- GLP-1 receptor agonist → delayed gastric emptying + appetite suppression
- Phase 3 trials: 14.9% mean weight loss at 68 weeks
- Weekly subcutaneous
- GI side effects in 30–45% during titration
- Gold standard pharmacological weight loss intervention with FDA approval